THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Michael Ihnat to Antineoplastic Agents

This is a "connection" page, showing publications Michael Ihnat has written about Antineoplastic Agents.
Connection Strength

1.906
  1. Identification of novel drugs to target dormant micrometastases. BMC Cancer. 2015 May 14; 15:404.
    View in: PubMed
    Score: 0.329
  2. A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. J Pharmacol Exp Ther. 2015 May; 353(2):392-404.
    View in: PubMed
    Score: 0.324
  3. Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure-activity relationship, in vitro and in vivo evaluation as antitumor agents. Bioorg Med Chem Lett. 2021 06 01; 41:127923.
    View in: PubMed
    Score: 0.123
  4. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem. 2021 04 01; 35:116061.
    View in: PubMed
    Score: 0.122
  5. The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity. Bioorg Med Chem. 2021 01 01; 29:115887.
    View in: PubMed
    Score: 0.121
  6. Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. Bioorg Med Chem Lett. 2018 10 01; 28(18):3085-3093.
    View in: PubMed
    Score: 0.103
  7. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res. 1997 Aug; 3(8):1339-46.
    View in: PubMed
    Score: 0.096
  8. Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett. 2017 04 01; 27(7):1602-1607.
    View in: PubMed
    Score: 0.093
  9. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorg Med Chem. 2017 01 15; 25(2):545-556.
    View in: PubMed
    Score: 0.091
  10. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem. 2014 Jul 15; 22(14):3753-72.
    View in: PubMed
    Score: 0.077
  11. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents. Bioorg Med Chem. 2013 Mar 01; 21(5):1312-23.
    View in: PubMed
    Score: 0.070
  12. Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem. 2012 Jul 15; 20(14):4217-25.
    View in: PubMed
    Score: 0.067
  13. Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. Bioorg Med Chem. 2010 May 15; 18(10):3575-87.
    View in: PubMed
    Score: 0.058
  14. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. J Med Chem. 2010 Feb 25; 53(4):1563-78.
    View in: PubMed
    Score: 0.057
  15. Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling. Mol Pharmacol. 2009 Sep; 76(3):588-95.
    View in: PubMed
    Score: 0.055
  16. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Bioorg Med Chem. 2005 Sep 15; 13(18):5475-91.
    View in: PubMed
    Score: 0.042
  17. Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases. Bioorg Med Chem. 2003 Nov 17; 11(23):5155-70.
    View in: PubMed
    Score: 0.037
  18. Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers. Mol Pharmacol. 1999 May; 55(5):938-47.
    View in: PubMed
    Score: 0.027
  19. N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors. Bioorg Med Chem. 2012 Jan 15; 20(2):910-4.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES